Vertex Pharma (VRTX) Tops Q1 EPS by 13c

Vertex Reports First Quarter 2015 Financial Results

April 29, 2015 4:01 PM EDT

-First quarter 2015 total revenues of $139 million, including net product revenues of $130 million for KALYDECO® (ivacaftor) in cystic fibrosis-

-Cash, cash equivalents and marketable securities of approximately $1.2 billion on March 31, 2015-

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2015. Vertex also reiterated its financial guidance for total 2015 KALYDECO revenues and non-GAAP operating expenses. Key financial results include:

            Three Months Ended March 31,       Increase/(Decrease) 2015     2014 $     % (in millions, except per share data)     KALYDECO product revenues, net $ 130.2 $ 99.5 $ 30.7 31 % GAAP net loss $ (198.6 ) $... More